The "Rolling Review" process had started, the EMA announced on Tuesday. Some of the data for approval are already being scrutinized, even if they are not yet complete.
This is intended to accelerate the approval process. The fact that the process was started at all shows that certain information suggests effectiveness. Corresponding laboratory data and data from clinical studies have been submitted that suggest that the vaccine triggers the production of antibodies, the EMA said on Tuesday. However, approval will only be granted if there is sufficient information on effectiveness, tolerability and quality, it said. The Sinovac active ingredient is a dead vaccine that contains inactivated virus particles and aluminum hydroxide to strengthen the immune response.